Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AmerisourceBergen

AvalonBay Communities

Cisco Systems

CVS Health

Federal Realty Investment Trust

General Dynamics

Intel

Realty Income Corp

Prudential Financial

Reinsurance Group of America

Siemens AG

Snap-on

Simon Property Group

The time has come once again to look at what sort of companies you'll want to be buying, this time as we move into October of 2020.

October 2020 Stocks: Financials, Real Estate, Industrials, IT And Pharma

IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020. The scheduled times (noted in...

Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting

Enterprise Products Partners

Gilead Sciences

Ingredion

Urstadt Biddle Properties

5 Dividend Stocks That Remain Good Buys In This Roller Coaster Market

Buying shares of companies trading well above off their average valuation and dividend yield can mean adding a stock with significant growth potential.

AbbVie Is Undervalued and Offers a High Yield

Builders FirstSource

Cia de Saneamento Basico do Estado de Sao Paulo

As of Oct. 2, the following stocks seem to be undervalued by the market, as their price-earnings ratios are below 20 and their price-earnings to growth (PEG) ratios stand below 1. Furthermore, these stocks have received positive recommendation ratings from sell-side analysts on Wall Street.

A Trio of Potential Bargains for the Value Investor

Boston Scientific

Medtronic

Stryker

Zimmer Biomet Hlds

While technology has been the engine that has driven stock market performance for some time now, increasingly we are seeing a seismic shift to health care among many portfolio managers, and with good reason.

Top Analyst Very Positive on Leading Medical Technology Health Care Stocks for 2021

LOS ANGELES--(BUSINESS WIRE)---- $ABBV #ABBV--ABBV LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against AbbVie Inc.

ABBV LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against AbbVie Inc. and Encourages Investors with Losses to Contact the Firm

Altria

ONEOK

AT&T

Takeda Pharmaceutical

Chasing high yields alone will ruin an income investor’s returns, so we look at these picks that offer a balance of stability and dividend income growth. The post 7 Dividend Stocks Perfect for a Retiree’s Portfolio appeared first on InvestorPlace.

7 Dividend Stocks Perfect for a Retiree’s Portfolio

A federal appeals court on Wednesday reversed an order that had required AbbVie Inc and a partner to disgorge $448 million in profit, in antitrust litigation brought by the U.S. Federal Trade Commission related to the testosterone replacement drug AndroGel.

U.S. court voids $448 million award against AbbVie, AndroGel partner

AbbVie's (ABBV) elezanumab is presently being evaluated in a phase II study for spinal cord injury.

AbbVie Elezanumab Gets FDA's Fast Track and Orphan Drug Tags

AbbVie could turn out to be a top-notch investment despite the upcoming expiration of its Humira patent.

4 Reasons AbbVie Is More Attractive Than You Think

Lockheed Martin

STORE Capital

4 Dividend Growth Opportunities To Benefit From Market Decline

2020 is shaping up to be another record year for AbbVie.

AbbVie: I Don't Wanna Miss This Thing

AbbVie (ABBV) closed the most recent trading day at $89.09, moving -1.13% from the previous trading session.

AbbVie (ABBV) Stock Moves -1.13%: What You Should Know

Micron Technology

Seagate Technology Holdings PLC

Teva Pharmaceutical

Walgreens

Western Digital

The stock market may have forgotten about these seven undervalued stocks, but you can pick them up now on the cheap. 
The post 7 Undervalued Stocks With Massive Potential appeared first on InvestorPlace.

7 Undervalued Stocks With Massive Potential

Generous dividends and long-term staying power make these two companies appealing to buy at a bargain.

2 Great Pharma Stocks to Buy in the Next Market Crash

Bristol-Myers

Most stocks are anything but cheap right now. These are three great exceptions.

3 Cheap Stocks You Can Buy and Hold for Decades

AbbVie - Still A 20% Undervalued, High-Yielding Buy

AbbVie: High Yield Dividend Anxiety

Automatic Data Processing

Carlisle Companies

Johnson & Johnson

Coca-Cola

Skyworks Solutions

Juicy dividends or explosive growth stocks? Most investors don't want to choose.

6 Dividend Stocks To Buy For Stable Yield And Growth Potential

AbbVie: The Best Dividend Growth Challenger In The Margin Of Safety

Morgan Stanley

AbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

Cardinal Health

Con Ed

People's United Financial

Often when income investors look for companies paying big dividends, they are drawn to the Dividend Aristocrats, and with good reason.

5 Dividend Aristocrat Stocks That Are Quietly Offering Huge Total Return Potential

Home Depot

QUALCOMM

Investors might want to consider buying stocks that also provide income via dividends given the current interest rate environment.

3 Stocks to Buy Now for Growth & Dividends to Counter Low Bond Yields

Investors can still own AbbVie stock at a good price, even in the wake of a potentially lifesaving collaboration.
The post Great Yield and Packed Pipeline Signal a Buy for AbbVie appeared first on InvestorPlace.

Great Yield and Packed Pipeline Signal a Buy for AbbVie

News for AbbVie Stock (ABBV)